早期乳腺癌辅助化疗之“去蒽环”之争
Debate of “nonanthracycline regimen” for adjuvant chemotherapy of early-stage breast cancer

蒽环类药物是乳腺癌术后辅助化疗的基石，但随着紫杉类药物和靶向药物如曲妥株单抗等新型抗肿 瘤药物的出现，再加上蒽环类药物固有的心脏毒性，使得人们开始思考，蒽环类药物在早期乳腺癌辅助化疗中是 否还有继续存在的价值。多项临床研究也开始了不含蒽环方案的尝试，包括US Oncology 9735、ABC、WSG Plan B、 Success C、BCIRG 006等研究。本文就“去蒽环”的相关临床研究作一梳理，为蒽环类药物在早期乳腺癌辅助化 疗中的治疗提供证据支持。
Anthracycline drugs are the cornerstone of postoperative adjuvant chemotherapy for breast cancer. Because of the inherent heart toxicity of anthracycline and the emergence of new anticancer drugs such as paclitaxel and targeted drugs, it has been considered whether anthracycline drugs should be remained as a regimen of the early breast cancer adjuvant chemotherapy or not. Several clinical studies have tried to discard anthracycline in the adjuvant treatment, including US Oncology 9735, ABC, WSG Plan B, Success C and BCIRG 006 researches, etc. In this paper, we reviewed the related clinical researches of “nonanthracycline regimen” to provide evidence of anthracycline used for the early breast cancer adjuvant chemotherapy